7,676 results match your criteria American Journal of Transplantation[Journal]


Letter to the editor concerning "Liver transplantation for metastatic wild-type gastrointestinal stromal tumor in the era of molecular targeted therapies: Report of a first case".

Am J Transplant 2020 May 28. Epub 2020 May 28.

Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.

A case report by Iesari et al. states that liver transplantation (LT) could be an effective treatment option for liver metastatic wild-type (WT) gastrointestinal stromal tumor (GIST). Although we find this therapeutic approach very challenging, we believe that this statement requires some clarifications due to following observations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.16076DOI Listing

Extinguishing burnout: National analysis of predictors and effects of burnout in abdominal transplant surgery fellows.

Am J Transplant 2020 May 28. Epub 2020 May 28.

Cincinnati Research on Education in Surgical Training (CREST), Cincinnati, Ohio, USA.

Burnout among surgeons has been attributed to increased workload and decreased autonomy. Although prior studies have examined burnout among transplant surgeons, no studies have evaluated burnout in abdominal transplant surgery fellows. The objective of our study was to identify predictors of burnout and understand its impact on personal and patient care during fellowship. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.16075DOI Listing

The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection.

Am J Transplant 2020 May 28. Epub 2020 May 28.

Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada.

The XV. Banff conference for allograft pathology was held in conjunction with the annual meeting of the American Society for Histocompatibility and Immunogenetics in Pittsburgh, PA (USA) and focused on refining recent updates to the classification, advances from the Banff working groups, and standardization of molecular diagnostics. This report on kidney transplant pathology details clarifications and refinements to the criteria for chronic active (CA) T cell-mediated rejection (TCMR), borderline, and antibody-mediated rejection (ABMR). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15898DOI Listing

Distinct peripheral blood molecular signature emerges with successful tacrolimus withdrawal in kidney transplant recipients.

Am J Transplant 2020 May 27. Epub 2020 May 27.

Department of Medicine, Icahn School of Medicine at Mount Sinai, Translational Transplant Research Center, New York, New York, USA.

Tacrolimus (Tac) is an effective anti-rejection agent in kidney transplantation, but its off-target effects make withdrawal desirable. Although studies indicate that Tac can be safely withdrawn in a subset of kidney transplant recipients, immune mechanisms that underlie successful vs unsuccessful Tac removal are unknown. We performed microarray analyses of peripheral blood mononuclear cells (PBMC) RNA from subjects enrolled in the Clinical Trials in Organ Transplantation-09 study in which we randomized stable kidney transplant recipients to Tac withdrawal or maintenance of standard immunosuppression beginning 6 months after transplant. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15979DOI Listing

Does Donor Muscularity "Pump Up" Living Donor Liver Transplant Survival?

Am J Transplant 2020 May 25. Epub 2020 May 25.

Department of Surgery, Division of Transplant Surgery, University of Virginia, Charlottesville, Virginia, USA.

Living donor liver transplantation (LDLT) emerged to mitigate the deceased donor organ shortage. While this approach has excellent recipient outcomes - similar to the ones achieved with a full graft - it has a clear advantage over the latter given it provides faster access to transplantation and reduces waiting list mortality. However, it is well known that the success of this approach has a strict relation with donor and graft selection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.16072DOI Listing

Evaluation of Ten Years Of Parainfluenza virus, human Metapneumovirus And Respiratory Syncytial Virus Infections In Lung Transplant Recipients.

Am J Transplant 2020 May 24. Epub 2020 May 24.

University of Groningen, University Medical Centre Groningen, Department of Pulmonary Diseases and Tuberculosis, Groningen, the Netherlands.

Respiratory tract infection with Pneumoviruses (PV) and Paramyxoviruses (PMV) are increasingly associated with chronic lung allograft dysfunction (CLAD) in lung transplant recipients (LTR). Ribavirin may be a treatment option but its effectiveness is unclear, especially with respect to infection severity. We retrospectively analyzed ten years of PV/PMV infections in LTR. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.16073DOI Listing

Specific organization for in-hospital belatacept infusion to avoid nosocomial transmission during the SARS-CoV-2 pandemic.

Am J Transplant 2020 May 24. Epub 2020 May 24.

Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France.

The first cases of Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) occurred in France in early February and in our region (Southwest France) in early March 2020. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.16074DOI Listing

Clinical outcome in solid organ transplant recipients with COVID-19: A single-center experience.

Am J Transplant 2020 May 21. Epub 2020 May 21.

Infectious Diseases Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

We read with great interest the report by Fernandéz-Ruiz and colleagues on the outcome of 18 transplant recipients with COVID-19, showing a higher case fatality rate than that reported in the general population. Unlike them, we did not observe higher mortality in transplant setting compared to our overall mortality. We collected data of 13 consecutive solid organ transplant recipients admitted to our Center for COVID-19 between February 21st and April 26th, 2020, with a median follow up of 36 days (IQR 25-41). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.16069DOI Listing

"Stoma or no stoma": First report of intestinal transplantation without stoma.

Am J Transplant 2020 May 20. Epub 2020 May 20.

Recanati Miller Transplantation Institute, Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, New York, United States.

Recent data suggests that frequent endoscopy and biopsy without evidence of graft dysfunction does not appear to confer survival advantage after intestinal transplantation. After abandoning protocol surveillance, endoscopic examination was decreased significantly at our center. These observations led us to question the need for stoma creation in intestinal transplantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.16065DOI Listing

Substituting imputation of HLA antigens for high resolution HLA typing: Evaluation of a multiethnic population and implications for clinical decision making in transplantation.

Am J Transplant 2020 May 20. Epub 2020 May 20.

Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States.

Molecular mismatch analysis for assessment of histocompatibility in transplantation requires high-resolution HLA typing. Algorithms to 'guesstimate' high-resolution from low-resolution typing exist, but their accuracy remains unknown. We converted high-resolution, sequence-based, HLA typing of 310 subjects from an ethnically heterogeneous population to low-resolution equivalents and tested the ability of the NMDP HaploStats and HLA Matchmaker programs to impute/reproduce the measured high-resolution HLA type, using the more common "winner-takes-all" approach. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.16070DOI Listing

Donor-to-recipient transmission and reactivation in a kidney transplant recipient of an inherited chromosomally integrated HHV-6A: Evidence and outcomes.

Am J Transplant 2020 May 19. Epub 2020 May 19.

CHU Lille, Service de Néphrologie, F-59000, Lille, France.

HHV-6A can be inherited and chromosomally integrated (iciHHV-6A), and donor to recipient transmission has been reported in solid-organ transplantation. However, when HHV-6A reactivation happens after transplantation, the source of HHV-6A is often not evident and its pathogenicity remains unclear. Here, we present an exhaustive case of donor-to-recipient transmission and reactivation of iciHHV-6A through kidney transplantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.16067DOI Listing

Banff 2019 Meeting Report: Molecular diagnostics in solid organ transplantation - Consensus for the Banff Human Organ Transplant (B-HOT) gene panel and open source multicenter validation.

Am J Transplant 2020 May 19. Epub 2020 May 19.

Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States.

This Meeting Report from the XV Banff conference describes the creation of a multi-organ transplant gene panel by the Banff Molecular Diagnostics Working Group (MDWG). This Banff Human Organ Transplant (B-HOT) panel is the culmination of previous work by the MDWG to identify a broadly useful gene panel based on whole transcriptome technology. A data driven process distilled a gene list from peer reviewed comprehensive microarray studies that discovered and validated their use in kidney, liver, heart and lung transplant biopsies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.16059DOI Listing

Transfusion-transmitted and community-acquired cytomegalovirus: infection in seronegative solid organ transplant recipients receiving.

Am J Transplant 2020 May 19. Epub 2020 May 19.

Department of Medicine, University of Alberta, Edmonton, AB, Canada.

Solid organ transplant (SOT) recipients who are cytomegalovirus (CMV) seronegative (R-) and receive seronegative donor (D-) organs have a small but currently unquantified risk of both transfusion-transmitted CMV (TT-CMV) and community-acquired CMV (CA-CMV). We retrospectively studied the incidence and clinical symptoms of TT-CMV (infection <1 year post-transplant) and CA-CMV (infection >1 year post-transplant) in a cohort of D-/R- adult and pediatric SOT recipients receiving leukoreduced blood products not screened for CMV seronegativity transplanted at our center between 2000-2011. CMV infection was defined as IgG seroconversion or detectable CMV antigenemia/DNAemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.16066DOI Listing

Pharmacological approaches to antibody-mediated rejection - Are we getting closer?

Am J Transplant 2020 May 17. Epub 2020 May 17.

Duke Transplant Center, Department of Surgery, Duke University School of Medicine, Durham, North Carolina, USA.

Antibody-mediated rejection (AMR) is a leading causes of graft failure, leading to shortened survival of affected solid organs transplanted, and its sinister, insidious onset destroys organ function gradually, or in more florid cases immediately. Both HLA pre-sensitized patients and those who develop de novo alloantibody--the latter associated with inadequate immunosuppression-- pay a heavy price for this form of immune injury. While increased tacrolimus or bolus steroids reliably reverse T cell-meditated rejection, these strategies and many others are ineffective in reversing all but early (< 3 months) AMR once donor-specific antibody is generated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.16061DOI Listing

TOXic Signaling: How antigen accelerates T cell exhaustion during transplantation.

Authors:
Mandy L Ford

Am J Transplant 2020 May 18. Epub 2020 May 18.

Department of Surgery, Emory Transplant Center, Atlanta, Georgia.

Immunologists have known for a long time that chronic exposure to antigen results in T cell "burn out." It is a process that likely underlies the observation that allergies can be cured by repeated shots of the offending substance. It may be responsible for the inability of carriers of congenitally-transmitted retroviruses to respond to viral antigens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.16060DOI Listing

First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study.

Am J Transplant 2020 May 15. Epub 2020 May 15.

Transplant Infectious Diseases Unit, University Hospitals of Geneva and , Faculty of Medicine, rue Gabrielle-Perret-Gentil 4, CH-1205, Genève, Switzerland.

Immunocompromised patients may be at increased risk for complications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, comprehensive data of SARS-CoV-2 infection in solid organ transplant (SOT) recipients are still lacking. We performed a multicenter nationwide observational study within the Swiss Transplant Cohort Study (STCS) to describe the epidemiology, clinical presentation, treatment and outcomes of the first microbiologically documented SARS-CoV-2 infection among SOT recipients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.16062DOI Listing

A comprehensive review of the impact of tacrolimus intrapatient variability on clinical outcomes in kidney transplantation.

Am J Transplant 2020 May 14. Epub 2020 May 14.

Department of Surgery, Medical University of South Carolina, Charleston, SC, USA.

Tacrolimus (Tac) is widely used to prevent rejection and graft loss in solid-organ transplantation. A limiting characteristic of Tac is the high intra and interpatient variability associated with its use. Routine therapeutic drug monitoring (TDM) is necessary to facilitate Tac management and avoid undesirable clinical outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.16002DOI Listing

A Change of Heart: Preliminary Results of the US 2018 Adult Heart Allocation Revision.

Am J Transplant 2020 May 14. Epub 2020 May 14.

Duke University School of Medicine and the Duke Clinical Research Institute, Durham, USA.

In 2018, the Organ Procurement and Transplantation Network (OPTN) modified adult heart allocation to better stratify candidates and provide broader access to the most medically urgent candidates. We analyzed OPTN data that included waiting list and transplant characteristics, geographical distribution, and early outcomes one year before (pre: 10/18/2017 - 10/17/2018) and following (post: 10/18/2018 - 10/17/2019) implementation. The number of adult heart transplants increased from 2954 pre- to 3032 post- implementation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.16010DOI Listing

Pre-transplant dialysis exposure and outcomes after kidney transplantation - where quantity and quality intersect?

Authors:
Alex Dinh Elaine Ku

Am J Transplant 2020 May 14. Epub 2020 May 14.

Division of Nephrology, Department of Medicine, University of California, San Francisco, California, USA.

Longer exposure to dialysis is a known risk factor for graft loss and mortality after kidney transplant. The accumulation of a greater burden of co-morbid conditions is one potential explanation for the observation of a higher risk of adverse transplant outcomes in patients with longer dialysis vintage. While some co-morbid conditions may improve after transplant (e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.16007DOI Listing

Superior inhibition of alloantibody responses with selective CD28 blockade is CTLA-4-dependent and T follicular helper cell-specific.

Am J Transplant 2020 May 13. Epub 2020 May 13.

Emory Transplant Center, Atlanta, GA, USA.

Anti-donor antibodies cause immunologic injury in transplantation. CD28 blockade with CTLA-4-Ig has the ability to reduce the incidence of these donor-specific antibodies (DSA), but its mechanism is suboptimal for the inhibition of alloimmunity in that CTLA-4-Ig blocks both CD28 costimulation and CTLA-4 coinhibition. Thus selective CD28 blockade that spares CTLA-4 has potential to result in improved inhibition of humoral alloimmunity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.16004DOI Listing

Mild COVID-19 in a pediatric renal transplant recipient.

Am J Transplant 2020 May 13. Epub 2020 May 13.

Division of Pediatric Nephrology, Department of Pediatrics, University of Florida, Gainesville, FL, 32608, USA.

As of mid-April 2020, the coronavirus disease of 2019 (COVID-19) pandemic has affected more than 2 million people and caused 135,000 deaths worldwide. Not much is known about the effect of this disease in immunosuppressed children with renal transplantation (RT). Here we report a 13-year-old child with multiple comorbidities who acquired COVID-19 five years post-RT in the United States. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.16003DOI Listing

New Frontiers in Urologic Organ Transplantation.

Am J Transplant 2020 May 14. Epub 2020 May 14.

MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital and the Center for Translational Transplant Medicine, Georgetown University Medical Center, Washington, DC, USA.

This edition of the AJT features a study entitled "Introducing A Novel Experimental Model of Bladder Transplantation In Mice" (1). The authors performed bladder transplantation on 16 syngeneic C57BL/6J mice and were able to demonstrate feasibility and functionality. Specifically, transplanted mice showed similar long-term body weight as control mice, as well as comparable ability of fully voiding urine volume both at 1-month and 6-month time intervals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.16008DOI Listing

Three-year outcomes from the CRADLE study in de novo pediatric kidney transplant recipients receiving everolimus with reduced tacrolimus and early steroid withdrawal.

Am J Transplant 2020 May 14. Epub 2020 May 14.

Novartis Pharma AG, Basel, Switzerland.

CRADLE was a 36-month multicenter study in pediatric (≥1 to <18 years) kidney transplant recipients randomized at 4-6 weeks post-transplantation to receive everolimus+reduced-exposure tacrolimus (EVR+rTAC; N=52) with corticosteriod withdrawal at 6-month post-transplantation or continue mycophenolate mofetil+standard-exposure TAC (MMF+sTAC; N=54) with corticosteroids. The incidence of composite efficacy failure (biopsy-proven acute rejection [BPAR], graft loss, or death) at Month 36 was 9.8% versus 9. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.16005DOI Listing

Reply to: High-grade urothelial carcinoma in a kidney transplant recipient after JC virus nephropathy: The first evidence of JC virus as a potential oncovirus in bladder cancer.

Am J Transplant 2020 May 14. Epub 2020 May 14.

Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.

We read with interest the recent article by Querido et al regarding the JC virus related urothelial carcinoma after kidney transplantation (1). In Taiwan and China, the upper urinary tract urothelial carcinoma (UT-UC) is a relatively prevalent disease and the risk of post kidney transplantation (KT) urothelial carcinoma increases up to 31-fold compared with general population (2,3). Positive JC virus DNA was reported up to 90. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.16006DOI Listing
May 2020
5.683 Impact Factor

Third-party vessel allografts in kidney and pancreas transplantation: Utilization, de novo DSA and Outcomes.

Am J Transplant 2020 May 13. Epub 2020 May 13.

Division of Nephrology, Department of Medicine, University of Wisconsin, School of Medicine and Public Health, Madison, WI, USA.

Third-party vascular allografts (VA) are an invaluable resource in kidney and pancreas transplantation when vascular reconstruction is needed and additional vessels from the organ donor are not available. We report the largest single-center experience to date on VA use, at a high-volume US transplant center. Over a 7-year period, VA were used for vascular reconstruction of 65 kidneys and 5 pancreases, in 69 recipients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.16009DOI Listing

Coronavirus disease 2019 and transplantation: The combination of lopinavir/ritonavir and hydroxychloroquine is responsible for excessive tacrolimus trough level and unfavorable outcome.

Am J Transplant 2020 May 13. Epub 2020 May 13.

Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China, 430071.

The ongoing outbreak of coronavirus disease 2019 (COVID-19) first reported in Wuhan has been declared global public health emergency and a pandemic by the World Health Organization. Faced with this novel coronavirus, scientists have been trying to use drugs that have not been validated by rigorous clinical trials, such as lopinavir/ritonavir (LPV/r) and hydroxychloroquine (HCQ). These drugs may be used tentatively for general population with COVID-19, but for solid organ transplant (SOT) recipients with long-term immunosuppressive therapy and drug-related metabolic diseases, antiviral drugs should be chosen with particular care. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15992DOI Listing

The inhibition of eIF5A hypusination by GC7, a preconditioning protocol to prevent brain death-induced renal injuries in a preclinical porcine kidney transplantation model.

Am J Transplant 2020 May 13. Epub 2020 May 13.

INSERM, UMR-1082 IRTOMIT, Poitiers, F-86021, France.

The eIF5A hypusination inhibitor GC7 (N1-guanyl-1,7-diaminoheptane) was shown to protect from ischemic injuries. We hypothesized that GC7 could be useful for preconditioning kidneys from donors prior transplantation. Using a preclinical porcine brain-death (BD) donation model, we carried out in vivo evaluation of GC7 pre-treatment (3 mg/kg iv, 5 min after BD) at the beginning of the 4h-donor management, after which kidneys were collected, cold-stored (18h in UW) and one was allo-transplanted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15994DOI Listing

Viral Shedding Prolongation in a Kidney Transplant Patient with COVID-19 Pneumonia.

Am J Transplant 2020 May 13. Epub 2020 May 13.

Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.

Coronavirus disease 2019 (COVID-19) pandemic sweeps the globe. The information regarding the kinetic changes of SARS-CoV-2 in immunosuppressed patients is unclear. Herein, we present a case of prolonged viral shedding in a transplant patient with COVID-19 pneumonia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15996DOI Listing

Effect of Preservation Solutions for Static Cold Storage on Kidney Transplantation Outcomes: a National Registry Study.

Am J Transplant 2020 May 13. Epub 2020 May 13.

Organ and Tissue Procurement and Transplantation Department, Agence de la biomédecine, Saint Denis La Plaine, France.

This study aimed to evaluate how five preservation solutions for static cold storage affected kidney transplant outcomes. It included all first single kidney transplants during 2010-2014 from donations after brain death in the French national transplant registry, excluding preemptive transplants and transplants of kidneys preserved with a hypothermic perfusion machine. The effects of each preservation solution on delayed graft function (DGF) and one-year transplant failure were evaluated with hierarchical multivariable logistic regression models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15995DOI Listing

Novel Corona Virus 2019 pneumonia in a kidney transplant recipient.

Am J Transplant 2020 May 13. Epub 2020 May 13.

Miller School of Medicine, University of Miami, Miami, USA.

COVID 19 pandemic is spreading worldwide and the impact of the disease in transplant patients is evolving. In this case report, we presented a 63 years old female kidney transplant recipient who presented with dyspnea and cough and diagnosed with COVID 19 pneumonia. On the 4 day of admission, the patient's condition worsened. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15999DOI Listing

Use of SARS-CoV-2 infected deceased organ donors: Should we always "just say no?"

Am J Transplant 2020 May 12. Epub 2020 May 12.

Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.

In the context of a rapidly evolving pandemic, multiple organizations have released guidelines stating that all organs from potential deceased donors with SARS-CoV-2 infection should be deferred, including from otherwise medically eligible donors found to have mild or asymptomatic SARS-CoV-2 discovered on routine donor screening. In this manuscript, we critically examine the available data on the risk of transmission of SARS-CoV-2 through organ transplantation. The isolation of SARS-CoV-2 from non-lung clinical specimens, the detection of SARS-CoV-2 in autopsy specimens, previous experience with the related coronaviruses SARS-CoV and MERS-CoV, and the vast experience with other common RNA respiratory viruses are all addressed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.16000DOI Listing

SARS-CoV-2 infection in two patients following recent lung transplantation.

Am J Transplant 2020 May 12. Epub 2020 May 12.

Department of Internal Medicine V, University of Munich, LMU, Comprehensive Pneumology Center, (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes Coronavirus disease 2019 (COVID-19) has become a world spreading health problem with pandemic character. Lung transplant recipients may be particularly at risk due to the high degree of immunosupression and the lung being the organ primarily affected by COVID-19. We describe a 16-year old male and a 64-year old female recently lung transplanted patients with COVID-19 during inpatient rehabilitation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15998DOI Listing

COVID-19 pneumonia in lung transplant recipients: report of two cases.

Am J Transplant 2020 May 12. Epub 2020 May 12.

Thoracic Surgery and Lung Transplant Center, Department of Cardio-Thoracic, Vascular Sciences and Public Health, Padova University-Hospital, Italy.

Coronavirus disease 2019 (COVID-19) has been declared pandemic since March 2020. In Europe, Italy has been the first nation affected by this infection. In this paper we report anamnestic data, clinical features and therapeutic management of two lung transplant recipients with confirmed COVID-19 pneumonia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15993DOI Listing

COVID-19 and islet transplantation: different twins.

Am J Transplant 2020 May 13. Epub 2020 May 13.

Università Vita-Salute San Raffaele, 20132, Milano, Italy.

For those who work in the field of islet transplantation, the micro vascular COVID-19 lung vessels obstructive thrombo-inflammatory syndrome (recently referred to as MicroCLOTS) is familiar, as one cannot fail to recognize the presence of similarities with the instant blood mediated inflammatory reaction (IBMIR) occurring in the liver hours and days after islet infusion. Evidences in both MicroCLOTS and IBMIR suggest the involvement of the coagulation cascade and complement system activation, and proinflammatory chemokines/cytokines release. Identification and targeting of pathway(s) playing a role as "master regulator(s)" in the post-islet transplant detrimental inflammatory events could be potentially useful to suggest innovative COVID-19 treatments and vice versa. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.16001DOI Listing

A case of coronavirus disease 2019-infected liver transplant donor.

Am J Transplant 2020 May 12. Epub 2020 May 12.

Department of Internal Medicine, Daegu Catholic University Medical Center, Daegu, Republic of Korea.

Coronavirus disease 2019 (COVID-19) is a novel infectious disease that continues to spread on a global scale. There has been growing concern about donor-derived transmissions of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Herein, we present the case of a patient who underwent ABO-incompatible living donor liver transplantation without knowing that the liver donor was infected with COVID-19 during the donation procedure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15997DOI Listing

Glimmers of hope for intestinal transplantation.

Am J Transplant 2020 May 8. Epub 2020 May 8.

MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital and the Center for Translational Transplant Medicine, Georgetown University Medical Center, Washington, District of Columbia, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15984DOI Listing

Abnormal liver enzymes in a liver transplant recipient.

Am J Transplant 2020 May 8. Epub 2020 May 8.

Department of Solid Organ Transplantation, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States.

A 68-year-old male with nonalcoholic steatohepatitis-related cirrhosis and hepatocellular carcinoma underwent orthotopic liver transplant (OLT) using an allograft from a 24-year-old donor after circulatory death (DCD). Functional warm ischemia time (fWIT) and cold ischemia time (CIT) were 26 and 512 minutes, respectively. Intraoperative estimated blood loss was 750 ml. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15977DOI Listing
May 2020
5.683 Impact Factor

Guidelines for standardized nomenclature and reporting in uterus transplantation: An opinion from the United States Uterus Transplant Consortium.

Am J Transplant 2020 May 7. Epub 2020 May 7.

Division of Transplantation, Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Uterus transplantation is a nascent but growing field. To support this growth, the United States Uterus Transplant Consortium proposes guidelines for nomenclature related to operative technique, vascular anatomy, and donor, recipient, and offspring outcomes. In terms of anatomy, the group recommends reporting donor arterial inflow and recipient anastomotic site delivering inflow to the graft and offers standardization of the names for the 4 veins originating from the uterus because of current inconsistency in this particular nomenclature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15973DOI Listing

Visfatin serum concentration is associated with cardiac allograft vasculopathy in heart transplant recipients.

Am J Transplant 2020 May 7. Epub 2020 May 7.

3rd Department of Cardiology, School of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.

Cardiac allograft vasculopathy (CAV) still is one of the most important limiting factors of long-term survival following heart transplantation (HT). This study aimed to investigate the association between proinflammatory adipokine-visfatin and the incidence of CAV in HT recipients. 182 patients after HT who had a follow-up visit at the Transplantation Clinic between 2016 and 2017 were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15986DOI Listing

Early experience of COVID-19 in 2 heart transplant recipients: Case reports and review of treatment options.

Am J Transplant 2020 May 7. Epub 2020 May 7.

Department of Medicine, Division of Cardiology, University of Chicago, Chicago, Illinois, USA.

The coronavirus disease 2019 (COVID-19) pandemic poses special challenges to immunocompromised transplant patients. Given the paucity of proven data in treating COVID-19, management of these patients is difficult, rapidly evolving, and mainly based on anecdotal experience. We report 2 cases of heart transplant (HT) recipients with COVID-19. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15982DOI Listing

Rejection in the setting of non-HLA antibody: New tools for navigating bench to bedside.

Am J Transplant 2020 May 5. Epub 2020 May 5.

Department of Pathology, Duke University, Durham, North Carolina, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15975DOI Listing

Living-donor liver transplantation for liver hemorrhaging due to peliosis hepatis in X-linked myotubular myopathy: Two cases and a literature review.

Am J Transplant 2020 May 6. Epub 2020 May 6.

Organ Transplantation Center, National Center for Child Health and Development, Tokyo, Japan.

X-linked myotubular myopathy (MTM) (OMIM 310400) is a severe neuromuscular disorder caused by mutations in the myotubularin (MTM1) gene. Liver hemorrhaging due to peliosis hepatis (PH) is a fatal complication. We herein report two successful cases of living-donor liver transplantation (LDLT) for MTM patients due to liver hemorrhaging caused by PH and review previous reports. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15978DOI Listing

Cytomegalovirus Serologic Matching in Deceased Donor Kidney Allocation Optimizes High and Low Risk (D+R- and D-R-) Profiles and Does Not Adversely Affect Transplant Rates.

Am J Transplant 2020 May 6. Epub 2020 May 6.

Division of Nephrology, Oregon Health and Science University, Portland, OR, United States.

Cytomegalovirus (CMV) is a major cause of infection related morbidity and mortality in kidney transplantation. The most significant risk for developing CMV infection after transplant depends upon donor (D) and recipient (R) CMV serostatus. In 2012, our Organ Procurement Organization (OPO) began a novel pre transplant CMV prevention strategy via matching deceased kidney donors and recipients by CMV serostatus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15976DOI Listing

Estimating the potential pool of uncontrolled DCD donors in the United States.

Am J Transplant 2020 May 5. Epub 2020 May 5.

Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Organs from uncontrolled DCD donors (uDCDs) have expanded donation in Europe since the 1980s, but are seldom used in the United States. Cited barriers include lack of knowledge about the potential donor pool, lack of robust outcomes data, lack of standard donor eligibility criteria and preservation methods, and logistical and ethical challenges. To determine whether it would be appropriate to invest in addressing these barriers and building this practice, we sought to enumerate the potential pool of uDCD donors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15981DOI Listing

Intragraft Gene Expression in Native Kidney BK Virus Nephropathy versus T-Cell Mediated Rejection: Prospects for Molecular Diagnosis and Risk Prediction.

Am J Transplant 2020 May 5. Epub 2020 May 5.

Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada.

Novel tools are needed to improve diagnostic accuracy and risk prediction in BK virus nephropathy (BKVN). We assessed the utility of intragraft gene expression testing for these purposes. Eight hundred genes were measured in 110 archival samples, including a discovery cohort of native kidney BKVN (n=5) versus pure T-cell mediated rejection (TCMR; n=10). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15980DOI Listing

Kidney transplantation with pre-symptomatic COVID-19 positive surgeon.

Am J Transplant 2020 May 5. Epub 2020 May 5.

Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

In Italy the Coronavirus Disease 2019 (COVID-19) outbreak caused by SARS-CoV-2 is testing the national health system and the intensive care unit are at the limits of their capacity. Severe travel limitation and containment at home were applied, such as in the Chinese experience and isolation of the diseased patients to control the exponential trend of the infection spread. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15971DOI Listing

Utilization of deceased donors during a pandemic: An argument against using SARS-CoV-2 positive donors.

Am J Transplant 2020 May 5. Epub 2020 May 5.

Department of Medicine, Division of Hepatology, University of Miami Miller School of Medicine, Miami, Florida.

SARS-CoV-2 has rapidly become an unprecedented pandemic that has impacted society, disrupted hospital functions, strained healthcare resources and impacted the lives of transplant professionals. Despite this, organ failure and the need for transplantation continues throughout the United States. Considering the perpetual scarcity of deceased donor organs, Kates et al present a viewpoint that advocates for the utilization of COVID-19 positive donors in selected cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15969DOI Listing

Response to "The COVID-19 outbreak in Italy: Initial implications for organ transplantation programs".

Authors:
Roberto Cacciola

Am J Transplant 2020 May 4. Epub 2020 May 4.

University of Rome Tor Vergata, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15968DOI Listing

Clinical Course of COVID-19 in a Liver Transplant Recipient on Hemodialysis and Response to Tocilizumab Therapy: A Case Report.

Am J Transplant 2020 May 2. Epub 2020 May 2.

Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

The novel coronavirus disease 2019 (COVID-19) is a highly infectious and rapidly spreading disease. There are limited published data on the epidemiology and outcomes of COVID-19 infection among organ transplant recipients. After initial flulike symptoms, progression to an inflammatory phase may occur, characterized by cytokine release rapidly leading to respiratory and multiorgan failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15985DOI Listing